Genetic and pharmacological studies confirmed that claudin-3 loss induces Wnt/β-catenin activation, which is further exacerbated by Stat-3-activation and helps promote colon cancer [39]. This evidence concerns the gene CLDN3 and malignant colon neoplasm.